LONDON, June 29 (Reuters) - Sanofi-Aventis's diabetes drug Lantus may increase the risk of cancer, according to new but inconclusive studies from experts around Europe. Shares in the French drugmaker ...
BRIDGEWATER, N.J., June 26 /PRNewswire-FirstCall/ --Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) has just been made aware of data associated with a retrospective ...
(Reuters) - U.S. generics drugmaker Mylan said on Thursday that the United States Patent and Trademark Office had rejected Sanofi's infringement claims relating to insulin drug Lantus. Sanofi is ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback